Zymeworks Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a)
Departure of Directors or Certain Officers
On November 3,2025, Dr. Nancy Davidson, Dr. Neil Gallagher and Mr. Derek Miller submitted their resignations from their positions as members of our board of directors, including from any committee thereof, effective as of November 6,2025. None of the resignations of Dr. Davidson, Dr. Gallagher and Mr. Miller was the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Other Events
In connection with the resignations of Dr. Davidson, Dr. Gallagher and Mr. Miller, our board of directors approved the composition of its standing committees as set forth below. In addition, our board of directors approved the dissolution of our research and development committee effective as of November 6, 2025.
| Audit Committee | CompensationCommittee | Nominating andCorporate GovernanceCommittee |
|---|---|---|
| Carlos Campoy (Chair) | Susan Mahony (Chair) | Gregory Ciongoli (Chair) |
| Gregory Ciongoli | Robert Landry | Alessandra Cesano |
| Robert Landry | Oleg Nodelman | Oleg Nodelman |
(b)
None.
(c)
Rule 10b5-1 Trading Plans
During our last fiscal quarter, no director or officer, as defined in Rule 16a-1(f) of the Exchange Act, adopted orterminated a “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.